Vivesto will hold a live-streamed R&D Update on March 26 at 14:00 CET, focusing on the veterinary oncology product Paccal Vet and the company’s ongoing open clinical pilot study.

Vivesto recently announced that the first patient has been dosed in the company’s open-label, pilot clinical trial with Paccal Vet (paclitaxel micellar) in dogs with splenic hemangiosarcoma following splenectomy. An interim analysis is expected by the end of 2024.

The purpose of the event is to describe the increasing medical need for more veterinary oncology drugs and to present the ongoing clinical program with Paccal Vet and the regulatory pathway to a market-approved drug.

External speakers include Henrik Rönnberg, Professor in veterinary pharmacology at the Swedish University of Agricultural Sciences (SLU) in Uppsala, and Jim Perry, CEO of CASTR Alliance – the contract research organization (CRO) that is coordinating the study at the participating clinics in the United States. Vivesto’s CEO Erik Kinnman, Chief Medical Officer Heidi B. Ramstad and Chief Regulatory Officer Johanna Röstin will also participate.

The presentations will be followed by a Q&A session where questions can be submitted in advance via

The presentations will be held in English and can be followed via and will also be available afterwards on Vivesto’s website. No registration is required.


  • Introduction – Erik Kinnman
  • Medical need – Henrik Rönnberg
  • Paccal Vet pilot clinical trial – Heidi B. Ramstad
  • Clinical operations – CASTR Alliance
  • Regulatory pathway to market approval – Johanna Röstin
  • Q&A

About Paccal Vet

Vivesto’s drug candidate Paccal Vet consists of paclitaxel formulated with the company’s proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.

Previous clinical studies performed by Vivesto has demonstrated safety in more than 300 dogs. Also, anti-tumor activity has been shown in squamous cell carcinoma and non-resectable mammary carcinoma of stage III-V.